{"id":"gsk-investigational-vaccine-gsk1557482a","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a vaccine candidate, GSK1557482A likely works by priming the adaptive immune system to recognize and attack cells expressing target antigens. The vaccine formulation may include adjuvants or delivery systems to enhance immunogenicity and promote both cellular and humoral immune responses.","oneSentence":"GSK1557482A is an investigational therapeutic vaccine designed to stimulate immune responses against specific tumor-associated antigens or pathogens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:38.985Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Investigational indication under phase 3 evaluation (specific indication not publicly confirmed)"}]},"trialDetails":[{"nctId":"NCT00980005","phase":"PHASE3","title":"Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-13","conditions":"Influenza","enrollment":2116},{"nctId":"NCT00778895","phase":"PHASE2","title":"Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-10","conditions":"Influenza","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK investigational vaccine GSK1557482A","genericName":"GSK investigational vaccine GSK1557482A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK1557482A is an investigational therapeutic vaccine designed to stimulate immune responses against specific tumor-associated antigens or pathogens. Used for Investigational indication under phase 3 evaluation (specific indication not publicly confirmed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}